Bayer pays up to $2.45B for Perfuse to bolster its eye disease pipeline

What's the deal? BayerDealroom has a profile for this one. Try Dealroom → has agreed to acquire Perfuse TherapeuticsDealroom has a profile for this one. Try Dealroom →, a US clinical-stage biopharmaceutical company, for up to $2.45B — $300M upfront with up to $2.15B in development, regulatory, and commercial milestone payments.

The acquisition centres on PER-001, a once-daily oral small molecule drug in Phase II development for glaucoma and diabetic retinopathy — two of the leading causes of blindness globally.

PER-001 works by blocking endothelin receptors, proteins that constrict blood vessels and reduce blood flow to the optic nerve and retina. By restoring that blood flow, it aims to slow or halt disease progression in patients who do not respond adequately to existing treatments.

The drug's oral format is a potential commercial advantage over the injectable therapies that currently dominate the eye disease market.

Why now? Bayer has been rebuilding its pharmaceutical pipeline following patent cliffs on several major drugs, and ophthalmology is one of its stated priority areas.

The company already markets Eylea, one of the world's best-selling eye drugs for age-related macular degeneration, and sees eye disease as a durable growth category as the global population ages. PER-001 targets a different disease mechanism to Eylea, offering complementary rather than overlapping coverage.

The deal also reflects a broader wave of ophthalmology M&A. Eye disease treatments represent a large and growing market — glaucoma alone affects more than 80 million people worldwide — and the shift toward oral or less invasive treatments is a major commercial and clinical opportunity.

What could go wrong? PER-001 is in Phase II — a stage where many drugs that showed early promise have historically failed to demonstrate sufficient efficacy or safety in larger trials.

The milestone-heavy structure of the deal, with $300M upfront against a $2.45B ceiling, reflects Bayer's caution about that risk. Glaucoma is also a well-served market with multiple established treatment classes, and differentiating PER-001 commercially will require clear Phase III data.

Bayer itself is navigating a challenging period — it is managing significant litigation liabilities related to its Roundup herbicide and has been under investor pressure to streamline its portfolio and restore profitability.

The signal: The deal is part of a broader pharmaceutical industry shift toward targeted, mechanism-specific treatments for chronic eye diseases — conditions that were historically managed rather than treated.

Bayer is betting that PER-001's novel mechanism, combined with its oral format, can address a segment of the glaucoma and diabetic retinopathy population that current injectable anti-VEGF therapies do not serve well.

For Perfuse, the acquisition validates a focused, single-asset strategy that brought a differentiated small molecule from concept to mid-stage clinical development — and attracted one of the world's largest pharmaceutical companies as a buyer.

Sources:
Bayer
Business Wire
Reuters
Bloomberg
Wall Street Journal
Fierce Biotech
Morningstar

Image generated by AI

J.V.